FDA Grants Priority Review to Frontline Daratumumab for Multiple Myeloma

January 22, 2018 – The FDA has granted a priority review designation to daratumumab in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The designation was based on findings from the ALCYONE study, which were published in the New England Journal of Medicine and presented at the 2017 ASH Annual Meeting … (leggi tutto)